Akari Therapeutics PLC (NASDAQ:AKTX) has received a consensus rating of “Hold” from the six analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $9.00.
AKTX has been the subject of several research reports. Zacks Investment Research upgraded shares of Akari Therapeutics from a “sell” rating to a “hold” rating and set a $5.00 price objective for the company in a research report on Monday, November 13th. B. Riley initiated coverage on shares of Akari Therapeutics in a research report on Thursday, February 8th. They issued a “neutral” rating and a $3.00 price objective for the company. Finally, ValuEngine upgraded shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th.
A hedge fund recently bought a new stake in Akari Therapeutics stock. AWM Investment Company Inc. acquired a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 684,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,962,000. AWM Investment Company Inc. owned approximately 5.81% of Akari Therapeutics at the end of the most recent quarter. 21.05% of the stock is owned by institutional investors and hedge funds.
Akari Therapeutics (NASDAQ AKTX) traded down $0.14 on Thursday, reaching $2.41. 104,225 shares of the company’s stock traded hands, compared to its average volume of 230,661. The firm has a market cap of $38.91, a PE ratio of -0.90 and a beta of -8.61. Akari Therapeutics has a 52-week low of $2.06 and a 52-week high of $22.20.
Akari Therapeutics (NASDAQ:AKTX) last posted its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.91. equities research analysts expect that Akari Therapeutics will post -2.5 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/13/brokerages-set-akari-therapeutics-plc-aktx-pt-at-9-00.html.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.